Global Health Vision

Global Health News and Reports

FMS Global News Report

Global Fibromyalgia Syndrome (FMS) and Chronic Fatigue Syndrome (CFS) News.

Fibromyalgia syndrome : New developments in pharmacotherapy.

Harten P.
Schwerpunkt Rheumatologie, Sophienblatt 1, 24103, Kiel, Deutschland, p.harten@web.de.

Fibromyalgia syndrome (FMS) affects 2-10% of the adult population in industrial countries and although it is associated with substantial morbidity and disability, treatment options are unsatisfactory. The rapid growth of trials for FMS in recent years has resulted in new, evidence-based approaches to medical treatment. This review focuses on the randomized, controlled studies of newer pharmacological options for FMS, such as selective serotonin/norepinephrine reuptake inhibitors (duloxetine, milnacipran), inhibitors of voltage-gated calcium channels (pregabalin, gabapentin), dopamine-2/3-receptor agonists (pramipexole, ropirinole), sedative-hypnotic agents (sodium oxybate, modafinil, dronabinol), 5-HT3 antagonists (tropisetron) and others (tramadol, dextromethorphan, olanzapine).

Full Story:

Advertisements

October 10, 2007 - Posted by | Fibromyalgia, Fibromyalgia News, FMS Global News, Global News | , ,

1 Comment »

  1. […] unknown wrote an interesting post today onHere’s a quick excerpt […]

    Pingback by FMS Global News Report | October 10, 2007 | Reply


Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: